Amoy Diagnostics Co., Ltd (AmoyDx, SZSE:300685), a leading company in companion diagnostics for precision oncology, today announced that the AmoyDx Lung Cancer PCR Panel has been accepted as first-line screening for patients who will potentially benefit from targeted therapy in the Lung Cancer Genomic Screening Project for Individualized Medicine (LC-SCRUM) in Japan.
September 30, 2019
· 3 min read